The Multiple Myeloma Hub enhanced global knowledge of myeloma throughout Q2 2022

Press release: Available for immediate release

The Multiple Myeloma Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in multiple myeloma (MM). Throughout Q2 of 2022, the Multiple Myeloma Hub continued to promote significant developments in the treatment and research of MM.

The Multiple Myeloma Hub covered four key conferences in Q2 to ensure the MM community receive the latest news and insights in treatment and research.

In April, at the 3rd European Myeloma Network Meeting, the hub had the chance to have a discussion with steering committee members about the evolving definition of risk in MM. In May, the hub attended the 8th COMy Congress and covered sessions such as “Mechanisms of resistance in myeloma” and those discussing new immunotherapeutic targets. In June, the hub attended the 2022 ASCO Annual Meeting in Chicago, providing live social media coverage and conducting interviews with specialists on the latest research in cancer care. Later in June, the hub also virtually covered the EHA 2022 Congress, providing updates on cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data, as well as the latest innovative techniques, diagnostic tools, and risk-assessment strategies. The coverage provided for these congresses helped contribute to over 60,000 hub page views in Q2 and generated over 258,000 impressions on the hub’s social channels.

Reviewing the Multiple Myeloma Hub’s impact this quarter, Marta Llobet-Canela, Multiple Myeloma Content Lead at Scientific Education Support, said:

“As part of our commitment to continuously enhance the hub’s user experience, we have recently introduced a new drug and trial updates section on the Multiple Myeloma Hub, which provides users with the most recent regulatory updates for their area of interest. This new functionality, which imports all updates directly from the hub’s Twitter account, means all drug and trial updates can be easily viewed and searched for in a single location.

“By providing on-the-spot coverage of key congresses such as COMy, EHA, and ASCO on the hub’s Twitter account and as enduring content on the website, we bring education to those who cannot attend and ensure that they are able to have sight of educational messages and vital updates in MM.

“Activity such as this would not be possible without our supporters. We would like to take this opportunity to show our gratitude to our existing supporters—Pfizer, Sanofi, AbbVie, Bristol Myers Squibb, Genentech, Roche, Amgen, and Takeda. We would also like to thank our steering committee for their continued guidance and support.”

ENDS

For more information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About multiple myeloma (MM)

Multiple myeloma (MM) is a form of blood cancer that begins with aberrant plasma cells—a type of white blood cell—in the bone marrow. It's called MM as it frequently affects several bones in the body, including the spine, skull, pelvis, and ribs, preventing the bone marrow from producing enough healthy blood cells while damaging and weakening the affected bones. MM accounts for 15% of all blood malignancies and 2% of all cancers.

About the Multiple Myeloma Hub

The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge of MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.

Founded in partnership with the European School of Haematology (ESH) in 2017, the Multiple Myeloma Hub is guided by an international steering committee of experts in the field of MM. The steering committee meet regularly to discuss the performance of the Multiple Myeloma Hub and to devise action plans on how best to support the MM community and address any unmet educational needs.

Multiple Myeloma Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

• Pfizer
• AbbVie
• Bristol Myers Squibb
• Genentech

• Roche
• Amgen
• Takeda

If you are interested in becoming a Multiple Myeloma Hub supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and MPN Hub.

About the European School of Haematology (ESH)

The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in haematology.